Introduction: De novo drug design principles MCQs With Answer is an essential study resource for B. Pharm students learning modern drug discovery. This topic covers structure-based and ligand-based design, pharmacophore modeling, fragment-based approaches, scoring functions, molecular docking, generative algorithms, ADMET prediction, and lead optimization. Understanding concepts such as scaffold hopping, synthetic accessibility, QSAR descriptors, force fields, and multi-parameter optimization prepares students for computational workflows and rational design decisions. These MCQs emphasize core principles, practical challenges, common pitfalls, and validation metrics to build a strong foundation in computer-aided drug design. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. What is the primary goal of de novo drug design?
- To identify natural products in biological extracts
- To predict patient-specific drug dosing
- To generate novel chemical structures predicted to bind a biological target
- To sequence the genome of a target organism
Correct Answer: To generate novel chemical structures predicted to bind a biological target
Q2. Which strategy uses the 3D structure of the target protein to build new ligands?
- Ligand-based design
- Structure-based design
- High-throughput screening
- Pharmacokinetic modeling
Correct Answer: Structure-based design
Q3. Which method relies on known active ligands rather than the receptor structure?
- Structure-based design
- Fragment-based de novo design
- Ligand-based design
- Molecular dynamics-driven design
Correct Answer: Ligand-based design
Q4. What is a pharmacophore model?
- A 3D arrangement of steric and electronic features necessary for biological activity
- A chemical synthesis route for a lead compound
- A scoring function for docking
- An ADMET prediction algorithm
Correct Answer: A 3D arrangement of steric and electronic features necessary for biological activity
Q5. Fragment-based de novo design primarily involves which process?
- Linking or growing small chemical fragments inside the binding site
- Screening millions of commercial compounds without decomposition
- Predicting toxicology from whole-organism models
- Simulating full-length proteins in membrane environments
Correct Answer: Linking or growing small chemical fragments inside the binding site
Q6. Which of the following is a common scoring function category used in de novo design?
- Empirical, knowledge-based, and force-field-based scoring functions
- Quantum-only scoring
- Clinical endpoint scoring
- Petri-net scoring
Correct Answer: Empirical, knowledge-based, and force-field-based scoring functions
Q7. What does “synthetic accessibility” refer to in de novo design?
- The likelihood a candidate can be synthesized with practical chemistry
- The probability of a compound being orally absorbed in humans
- The chance of a molecule passing regulatory approval
- The number of chiral centers a molecule contains
Correct Answer: The likelihood a candidate can be synthesized with practical chemistry
Q8. Which rule set is commonly used to evaluate drug-likeness early in design?
- Le Chatelier’s principle
- Lipinski’s Rule of Five
- Henderson-Hasselbalch rules
- Michaelis-Menten guidelines
Correct Answer: Lipinski’s Rule of Five
Q9. In de novo design, what is “scaffold hopping”?
- Replacing a core scaffold to find new chemotypes retaining activity
- Using high-temperature reactions to create scaffolds
- Moving a scaffold physically between labs
- Scaling up synthesis for lead manufacturing
Correct Answer: Replacing a core scaffold to find new chemotypes retaining activity
Q10. Which computational approach generates novel molecules using neural networks or GANs?
- Empirical scoring
- Generative deep learning models
- Quantum annealing
- Classical force-field minimization alone
Correct Answer: Generative deep learning models
Q11. What does ADMET stand for and why is it important in de novo design?
- Absorption, Distribution, Metabolism, Excretion, Toxicity — evaluates pharmacokinetics and safety
- Affinity, Docking, Electrostatics, Modeling, Torsion — molecular mechanics terms
- Assay, Design, Evaluation, Manufacturing, Testing — development workflow
- Analytical, Diagnostic, Medicinal, Experimental, Therapeutic — clinical categories
Correct Answer: Absorption, Distribution, Metabolism, Excretion, Toxicity — evaluates pharmacokinetics and safety
Q12. Which metric assesses how well a predicted ligand pose matches the experimental pose?
- RMSD (Root Mean Square Deviation)
- pKa value
- Log P
- Minimal inhibitory concentration (MIC)
Correct Answer: RMSD (Root Mean Square Deviation)
Q13. Which pitfall is a known limitation of many scoring functions?
- Perfect prediction of ADMET properties
- Inability to rank binding affinities accurately due to entropic effects
- Always predicting correct synthetic routes
- Generating unlimited conformers instantly
Correct Answer: Inability to rank binding affinities accurately due to entropic effects
Q14. In fragment growing, what is a crucial consideration for linking fragments?
- Ensuring the linker maintains favorable geometry and interactions without strain
- Maximizing molecular weight regardless of binding
- Always using rigid aromatic linkers only
- Avoiding any hydrogen bond donors
Correct Answer: Ensuring the linker maintains favorable geometry and interactions without strain
Q15. What role does molecular dynamics (MD) play in structure-based de novo design?
- Simulating receptor flexibility and ligand stability over time
- Automatically synthesizing designed compounds
- Predicting clinical trial outcomes directly
- Replacing quantum mechanics for electronic properties in all cases
Correct Answer: Simulating receptor flexibility and ligand stability over time
Q16. Which descriptor type is commonly used in QSAR models supporting de novo design?
- Topological, physicochemical, and electronic molecular descriptors
- Clinical trial phase descriptors
- Only synthetic route counts
- Patient demographic descriptors
Correct Answer: Topological, physicochemical, and electronic molecular descriptors
Q17. What is multi-parameter optimization (MPO) in de novo design?
- Optimizing multiple properties such as potency, ADMET, and synthetic feasibility simultaneously
- Maximizing only binding affinity at all costs
- Focusing solely on aesthetic molecular shapes
- Optimizing only solubility and ignoring potency
Correct Answer: Optimizing multiple properties such as potency, ADMET, and synthetic feasibility simultaneously
Q18. Which is an example of a rule used to filter out problematic chemical structures?
- PAINS (Pan-Assay INterference compoundS) filters
- Golden Rule of Pharmacology
- Leucine Z-rule
- HOMO-LUMO exclusion rule
Correct Answer: PAINS (Pan-Assay INterference compoundS) filters
Q19. Which algorithmic approach incrementally modifies molecules using mutation and crossover concepts?
- Genetic algorithms
- Deterministic linear programming only
- Single-point molecular algebra
- Fourier transform generation
Correct Answer: Genetic algorithms
Q20. What is the main advantage of graph-based de novo design methods?
- They directly manipulate molecular graphs, enabling chemically valid structure generation
- They always guarantee crystal structures for the ligand
- They avoid any need for scoring functions
- They produce only peptides
Correct Answer: They directly manipulate molecular graphs, enabling chemically valid structure generation
Q21. Why is conformational sampling important in de novo design?
- To explore possible ligand shapes and ensure favorable binding conformations are considered
- To increase molecular weight artificially
- To reduce calculation time to zero
- To guarantee a single rigid pose for every ligand
Correct Answer: To explore possible ligand shapes and ensure favorable binding conformations are considered
Q22. Which validation metric measures the ability of a virtual screening method to enrich actives early?
- Enrichment factor (EF)
- Partition coefficient
- Synthetic accessibility score
- Boiling point
Correct Answer: Enrichment factor (EF)
Q23. What is a common strategy to reduce false positives from docking in de novo design?
- Use consensus scoring and rescoring with more rigorous methods
- Ignore all docking scores and pick randomly
- Only accept molecules with more than 100 heavy atoms
- Always choose highest molecular weight compounds
Correct Answer: Use consensus scoring and rescoring with more rigorous methods
Q24. Which property is reflected by LogP and is relevant in de novo design?
- Lipophilicity, influencing permeability and solubility
- Optical rotation
- Number of hydrogen bond acceptors only
- Refractive index
Correct Answer: Lipophilicity, influencing permeability and solubility
Q25. In de novo design, which of the following best describes “bioisosteric replacement”?
- Replacing a functional group with another that preserves activity but alters properties
- Changing an atom only to isotopic variants
- Adding toxicophores to increase potency
- Switching from organic to inorganic scaffolds exclusively
Correct Answer: Replacing a functional group with another that preserves activity but alters properties
Q26. Which tool category specifically helps propose synthetic routes for designed molecules?
- Retrosynthetic analysis and synthesis planning software
- Docking engines only
- MD integrators exclusively
- Quantum hardware controllers
Correct Answer: Retrosynthetic analysis and synthesis planning software
Q27. How does incorporation of receptor flexibility improve de novo design outcomes?
- By allowing design to account for induced fit and alternative binding site conformations
- By making scoring functions unnecessary
- By decreasing computational cost astronomically
- By preventing any ligand from binding
Correct Answer: By allowing design to account for induced fit and alternative binding site conformations
Q28. What is the purpose of using knowledge-based potentials in scoring?
- To use statistical information from known protein–ligand complexes to estimate interaction favorability
- To run quantum mechanical calculations at zero cost
- To physically synthesize ligands in silico
- To ensure molecules violate drug-likeness rules
Correct Answer: To use statistical information from known protein–ligand complexes to estimate interaction favorability
Q29. Which practice helps ensure de novo designs are less likely to fail later due to toxicity?
- Early incorporation of in silico toxicity and off-target prediction models
- Maximizing aromatic rings without regard for metabolism
- Only optimizing for binding energy in vacuum
- Avoiding any ADMET assessment until clinical trials
Correct Answer: Early incorporation of in silico toxicity and off-target prediction models
Q30. Which outcome indicates a successful de novo design campaign?
- Designed molecules that are synthetically feasible, show predicted target activity, acceptable ADMET, and experimental validation
- Only molecules with the largest molecular weights regardless of properties
- Complete reliance on a single docking score with no experiments
- Designs that always fail to bind but are easy to synthesize
Correct Answer: Designed molecules that are synthetically feasible, show predicted target activity, acceptable ADMET, and experimental validation
